Wixela Inhub vs. Fasenra

• Are Wixela Inhub and Fasenra the Same Thing?
• What Are Possible Side Effects of Wixela Inhub?
• What Are Possible Side Effects of Fasenra?
• What Is Wixela Inhub?
• What Is Fasenra?
• What Drugs Interact with Wixela Inhub?
• What Drugs Interact with Fasenra?
• How Should Wixela Inhub Be Taken?
• How Should Fasenra Be Taken?

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) and Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) are used to treat asthma.

Wixela Inhub is used for twice-daily treatment of asthma in patients aged 4 years and older and also for maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Fasenra is used for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Wixela Inhub and Fasenra belong to different drug classes. Wixela Inhub contains a combination of a corticosteroid and a long-acting beta-adrenergic agonist (LABA) and Fasenra is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa).

Side effects of Wixela Inhub and Fasenra that are similar include sore throat and headaches.

Side effects of Wixela Inhub that are different from Fasenra include upper respiratory tract infection or inflammation, hoarseness, oral thrush, bronchitis, cough, nausea, vomiting, pneumonia, and musculoskeletal pain.

Side effects of Fasenra that are different from Wixela Inhub include fever, hypersensitivity reactions, and injection site reactions (pain, redness, itching, or a small lump).

Wixela Inhub also interact with other medicines containing a LABA, antivirals, azole antifungals, clarithromycin, telithromycin, nefazodone, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, and diuretics.

Fasenra may interact with other drugs.

Common side effects of Wixela Inhub include:

• upper respiratory tract infection or inflammation,
• sore throat,
• hoarseness,
• oral thrush,
• bronchitis,
• cough,
• headaches,
• nausea and vomiting,
• pneumonia,
• viral respiratory infections, and
• musculoskeletal pain

Common side effects of Fasenra include:

• headache,
• sore throat,
• fever,
• hypersensitivity reactions, and
• injection site reactions (pain, redness, itching, or a small lump)

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) contains a combination of a corticosteroid and a long-acting beta-adrenergic agonist (LABA) indicated for twice-daily treatment of asthma in patients aged 4 years and older or maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Wixela Inhub is available in generic form.

Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Wixela Inhub may interact with additional medicines containing a LABA, ritonavir, ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, and diuretics. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Wixela Inhub; it is unknown how it would affect a fetus. It is unknown if Wixela Inhub passes into breast milk. Consult your doctor before breastfeeding.

Fasenra may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Fasenra; it is unknown how it would affect a fetus. Monoclonal antibodies such as Fasenra are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. It is unknown if Fasenra passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

The dose of Wixela Inhub for treatment of asthma in patients aged 12 years and older is 1 inhalation of Wixela Inhub 100/50, Wixela Inhub 250/50, or Wixela Inhub 500/50 twice daily. The dose of Wixela Inhub for treatment of asthma in patients aged 4 to 11 years is 1 inhalation of Wixela Inhub 100/50 twice daily. The dose of Wixela Inhub for maintenance treatment of COPD is 1 inhalation of Wixela Inhub 250/50 twice daily.

The dose of Fasenra is one tablet taken orally once daily with or without food.